Arctic Therapeutics ehf.

5 trials 1 recruiting Commercial sponsor Merged from 3 name variants

Filter these 5 trials by condition, phase, country and more.

Open in Search →

5 Registered trials

1 Recruiting

3 Completed trials

6 Countries active

4 Unique IMPs

100% Results reported

Phase II

100%

3 of 3 completed trials have published summary results (EU CTR Article 37 — 12-month obligation).

View full Transparency Scoreboard →

Top indications

Cerebral amyloid angiopathy 2 Psoriasis 1

Top IMPs

ACETYLCYSTEINE AMIDE 3 DONEPEZIL HYDROCHLORIDE 1 PEHERO 1

All trials

5 total

Safety, Tolerability and Efficacy of NPI-001 (AT-001) in Patients with Hereditary Cystatin C Amyloid Angiopathy (HCCAA) Not authorised

2023-503969-36-00 Phase II 1 country ACETYLCYSTEINE AMIDE
Safety, Tolerability and Biomarker-based Efficacy of NPI-001 (AT-001) in Subjects with Alzheimer’s Disease (AD) Recruiting

2024-519497-39-00 Phase II 2 countries ACETYLCYSTEINE AMIDE
Safety and Efficacy of AT-004 in Patients with Acne Vulgaris Ended

2025-521510-25-00 Phase II 1 country DONEPEZIL HYDROCHLORIDE
Safety, Tolerability and Efficacy of NPI-001 (AT-001) in Patients with Hereditary Cystatin C Amyloid Angiopathy (HCCAA) Ended

2023-503969-36-01 Phase II 1 country ACETYLCYSTEINE AMIDE
An efficacy and safety study of HRO350 in patients with mild-to-moderate psoriasis (the ‘HeROPA’ study) Ended

2022-501850-12-00 Phase II 4 countries PEHERO

Showing 1–5 of 5 trials

← All sponsors A–Z